{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T16:05:39Z","timestamp":1769702739482,"version":"3.49.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004480","name":"Natural Science Foundation of Shanxi Province","doi-asserted-by":"publisher","award":["202103021224001"],"award-info":[{"award-number":["202103021224001"]}],"id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Consolidative allogeneic hematopoietic stem cell transplantation (allo-HSCT) after chimeric antigen receptor (CAR) T-cell therapy is an emerging modality in hematologic malignancies. Knowledge regarding the optimal interval and pretreatment regimen between CAR T-cell therapy and allo-HSCT remains limited. Here, we report two cases of confirmed relapsed\/refractory (R\/R) T-cell acute lymphoblastic leukemia (T-ALL) treated with autologous anti-CD7 CAR T cells infusion bridging to allo-HSCT. Case 1 had a poor prognosis due to grade 3 cytokine release syndrome (CRS), infection, drug-related organ toxicity, hyperacute graft-versus-host disease (GVHD), and transplant-associated thrombotic microangiopathy (TA-TMA). In contrast, case 2 demonstrated a favorable course, marked by effective inflammation control, complete recovery following CAR T-cell therapy, and timely transplantation. These cases indicate that anti-CD7 CAR T-cell therapy represents a promising therapeutic strategy for R\/R T-ALL. However, its integration with allo-HSCT constitutes a high-risk clinical approach that requires careful and individualized management.<\/jats:p>","DOI":"10.3389\/fonc.2026.1766948","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T05:22:19Z","timestamp":1769664139000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case report: Different outcomes of two cases of relapsed\/refractory T cell acute lymphoblastic leukemia treated with anti-CD7 chimeric antigen receptor T cells bridging to allogeneic hematopoietic stem cell transplantation: from curative promise to fatal risk"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhijuan","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanru","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuting","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiping","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiqun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-231217","article-title":"T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII\/ECOG 2993)","volume":"114","author":"Marks","year":"2009","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1182\/blood-2011-04-347872","article-title":"Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007","volume":"119","author":"Dores","year":"2012","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.324.324","article-title":"Successful subtype oriented treatment strategies in adult T-All; results of 744 patients treated in three consecutive GMALL studies","volume":"114","author":"Hoelzer","year":"2009","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.312","article-title":"The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience","volume":"28","author":"Jain","year":"2014","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25896","article-title":"Outcome of adults with relapsed\/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma","volume":"95","author":"Samra","year":"2020","journal-title":"Am J Hematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022920","article-title":"Classification and risk stratification in T-lineage acute lymphoblastic leukemia","volume":"145","author":"P\u00f6l\u00f6nen","year":"2025","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00352-w","article-title":"Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia\/lymphoma","volume":"10","author":"Dai","year":"2022","journal-title":"biomark Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014498","article-title":"Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27094","article-title":"Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy","volume":"98","author":"Zhang","year":"2023","journal-title":"Am J Hematol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"73.e1","DOI":"10.1016\/j.jtct.2024.11.009","article-title":"CD7 CART therapy bridging allo-HSCT remarkably improves long-term DFS in refractory\/relapsed T-ALL\/LBL","volume":"31","author":"Li","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-023-01427-3","article-title":"Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia","volume":"16","author":"Tan","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181f24e8d","article-title":"Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation","volume":"90","author":"Cho","year":"2010","journal-title":"Transplantation"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00133","article-title":"Transplant-associated thrombotic microangiopathy in pediatric hematopoietic cell transplant recipients: A practical approach to diagnosis and management","volume":"7","author":"Dvorak","year":"2019","journal-title":"Front Pediatr"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.220752","article-title":"The role of complement in autoimmune disease-associated thrombotic microangiopathy and the potential for therapeutics","volume":"50","author":"Java","year":"2023","journal-title":"J Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21113886","article-title":"A new era in endothelial injury syndromes: toxicity of CAR-T cells and the role of immunity","volume":"21","author":"Gavriilaki","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.194","article-title":"Circulating endothelial cell count: a reliable marker of endothelial damage in patients undergoing hematopoietic stem cell transplantation","volume":"52","author":"Almici","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1033490","article-title":"Role of endothelial cells in graft-versus-host disease","volume":"13","author":"Neidemire-Colley","year":"2022","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.20180","article-title":"Higher risk of platelet engraftment failure and chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation following chimeric antigen receptor T-cell therapy compared to chemotherapy: A propensity score-matched analysis","volume":"207","author":"Yang","year":"2025","journal-title":"Br J Haematol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.21037\/tcr-22-174","article-title":"Allogeneic CAR-T bridging to allo-HSCT as a treatment strategy for refractory adult Burkitt\u2019s lymphoma: a case report","volume":"11","author":"Cheng","year":"2022","journal-title":"Transl Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2021.03.001","article-title":"Chinese consensus on the diagnosis and management of transplant-associated thrombotic microangiopathy (2021)","volume":"42","year":"2021","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017035","article-title":"How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia","volume":"141","author":"Kopmar","year":"2023","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e70006","DOI":"10.1111\/cts.70006","article-title":"Paired comparisons of venetoclax concentration in cerebrospinal fluid, bone marrow, and plasma in acute leukemia patients","volume":"17","author":"Jian","year":"2024","journal-title":"Clin Transl Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s44228-022-00019-1","article-title":"Azacitidine in combination with venetoclax maintenance post-allogeneic hematopoietic stem cell transplantation in T cell acute lymphoblastic leukemia","volume":"5","author":"Hassan","year":"2023","journal-title":"Clin Hematol Int"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2019.07.008","article-title":"The efficacy analysis of allogeneic hematopoietic stem cell transplantation in 48 leukemia patients with central nervous system leukemia","volume":"40","author":"Fei","year":"2019","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16339","article-title":"Chimeric antigens receptor T cell therapy as a bridge to haematopoietic stem cell transplantation for refractory\/relapsed B-cell acute lymphomalastic leukemia","volume":"189","author":"Zhang","year":"2020","journal-title":"Br J Haematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19445","article-title":"A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T-cell acute lymphoblastic leukaemia\/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen receptor T-cell therapy","volume":"204","author":"Cao","year":"2024","journal-title":"Br J Haematol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1186\/s12885-018-5037-7","article-title":"CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report","volume":"18","author":"Wen","year":"2018","journal-title":"BMC Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215721","article-title":"Unity brings strength: Combination of CAR-T cell therapy and HSCT","volume":"549","author":"Huang","year":"2022","journal-title":"Cancer Lett"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313812","article-title":"Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis","volume":"390","author":"Hu","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1766948\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T05:22:24Z","timestamp":1769664144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1766948\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":31,"alternative-id":["10.3389\/fonc.2026.1766948"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1766948","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"article-number":"1766948"}}